Akkermansia

Probiotic

Supplement category based on Akkermansia muciniphila, a mucin-associated gut bacterium. Products differ by strain, viable versus pasteurized form, cell count, and formulation. Early human trials are small and product-specific; microbiome abundance is not equivalent to systemic drug exposure.

Pharmacokinetic model

A route-level PK model for akkermansia is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Probiotic
Suggested cadence: once daily

Research behind this entry

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD · Nature Medicine, 2019 DOI
Single-center pilot randomized 40 insulin-resistant adults with overweight or obesity; 32 completed three months. Live and pasteurized preparations were tolerated, and the pasteurized arm changed several metabolic…
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD · Proceedings of the National Academy of Sciences, 2013 DOI
In mice, viable Akkermansia altered gut-barrier and metabolic measures in diet-induced obesity, whereas heat-killed cells did not reproduce those effects. The animal study demonstrates formulation dependence and cannot…

2 published studies referenced in the app, each with a plain-language summary.